New “Real World” Study of Immunotherapy for Peritoneal Mesothelioma

immunotherapy for peritoneal meosthelioma

A new study from one of the nation’s top cancer centers supports the role of immunotherapy in peritoneal mesothelioma treatment. Immunotherapy is a treatment approach that aims to harness the body’s natural defense system to fight cancer.  Several immunotherapy drugs have been tested for pleural mesothelioma. Pleural mesothelioma affects the lungs. Last year, the FDA approved a new combination of immunotherapy drugs for the pleural form of asbestos cancer.  But there is less data on immunotherapy for peritoneal mesothelioma. Researchers at MD Anderson Cancer Center just released their findings on a class of immunotherapy drugs called immune checkpoint inhibitors (ICIs). They say it is the first “real-world evidence” of clinical outcomes with ICIs in peritoneal mesothelioma patients. Immune Checkpoint Inhibitors … Continue reading New “Real World” Study of Immunotherapy for Peritoneal Mesothelioma »

Comparing Second-Line Therapies for Recurrent Mesothelioma

recurrent mesothelioma

University of Pennsylvania researchers have some hopeful news for people with recurrent mesothelioma after chemotherapy: Second-line immunotherapy might increase their odds of survival. Previous studies show that recurrent mesothelioma patients who had immunotherapy lived longer than those on placebo. But doctors were not sure how second-line immunotherapy compared to second-line chemotherapy in these patients. The new study showed a clear survival advantage for those who had immunotherapy.  Coping with Recurrent Mesothelioma Malignant pleural mesothelioma is a rare cancer with a grim prognosis. Most people who receive a mesothelioma diagnosis start treatment with chemotherapy. A combination of Alimta (pemetrexed) and a platinum drug is the most common first-line treatment.  But even the standard-of-care rarely keeps this virulent cancer at bay for … Continue reading Comparing Second-Line Therapies for Recurrent Mesothelioma »

New PD-L1 Inhibitor Could Make Mesothelioma Immunotherapy Safer

PD-L1 Inhibitor

A new PD-L1 inhibitor may be on the horizon for people with malignant mesothelioma. A Phase I trial suggests it may be safer than some previous immunotherapy drugs.  PD-L1 is a protein that helps mesothelioma cancer cells hide from the immune system. Several of the most promising immunotherapy drugs for mesothelioma block PD-L1. But the new PD-L1 inhibitor is different. CX-072 (pacmilimab) has the ability to specifically target the tumor. This could reduce the risk for dangerous side effects since normal cells are less likely to be affected.  San Francisco-based CytomX Therapeutics developed CX-072 and a team of international researchers has been studying it. This week, they released the findings of their Phase I trial. The trial included patients with … Continue reading New PD-L1 Inhibitor Could Make Mesothelioma Immunotherapy Safer »

CAR-T Cells + Keytruda: New Immunotherapy for Pleural Mesothelioma?

immunotherapy for pleural mesothelioma

Researchers at a top US cancer center are experimenting with a new approach to immunotherapy for pleural mesothelioma – with exciting results.  The research was done at Memorial Sloan Kettering Cancer Center in New York and published in a recent issue of Cancer Discovery.  The Phase I trial is the first to treat pleural mesothelioma patients with CAR-T cell therapy and the PD-1 blocker pembrolizumab (Keytruda). Although the trial was small, 83 percent of patients lived for more than a year. Some lived for nearly two.  Malignant Mesothelioma commonly claims the lives of patients within months. This new type of immunotherapy for pleural mesothelioma could be a breakthrough in improving survival. The Challenge of Malignant Mesothelioma Scientists have known about … Continue reading CAR-T Cells + Keytruda: New Immunotherapy for Pleural Mesothelioma? »

New Test May Help Doctors Choose the Best Mesothelioma Surgery

best mesothelioma surgery

A new predictive model may make it easier for cancer doctors to choose the best mesothelioma surgery for each pleural mesothelioma patient.  There are two major surgical approaches for pleural mesothelioma. One involves removal of a lung and the other does not.  Right now, the choice about which surgery to have is based on patient demographics, symptoms, and lab values. Which surgery is most common at the institution may also play a role. Many surgeons have strong opinions about which is the best mesothelioma surgery.   But Harvard researchers say the new predictive model they tested is a better way to stratify mesothelioma patients. Their study suggests that this approach may lead to better treatment outcomes and more accurate clinical trials.  … Continue reading New Test May Help Doctors Choose the Best Mesothelioma Surgery »

Study May Lead to Safer Immunotherapy for Mesothelioma

immunotherapy for mesothelioma

New research conducted in Europe and at Harvard University may open the door to safer immunotherapy for mesothelioma patients.  Immunotherapy is one of the most promising approaches to fight malignant mesothelioma. But the potential side effects can be devastating.  Now, new data suggests there are ways to reduce the complications of immunotherapy for mesothelioma. The key is to target some of the white blood cells that trigger inflammation. Inflammation is the driver behind most of the serious side effects of immunotherapy.  Why Harness the Immune System? No one ever expects to contract mesothelioma. It is an extremely rare cancer. Most people who get it have spent time living or working around asbestos. Even among asbestos-exposed people, mesothelioma is rare. Scientists … Continue reading Study May Lead to Safer Immunotherapy for Mesothelioma »

Early Data Show Promise for Galinpepimut-S and Opdivo in Mesothelioma Patients

galinpepimut-s and opdivo

A combination of the immunotherapy drugs galinpepimut-S and Opdivo may give mesothelioma patients a few extra months, according to newly-released data.  The clinical data is part of an ongoing study of galinpepimut-S and Opdivo. SELLAS Life Sciences Group, the makers of galinpepimut-S, released the latest findings this week.  Although the early data is based on just four mesothelioma cases, it appears to be promising. All of the study subjects had either relapsed after chemotherapy or failed to respond at all.  These patients had a median overall survival of 35.4 weeks on the combination of galinpepimut-S and Opdivo. Typical overall survival in relapsed patients with standard care is just 7 months.  Immunotherapy with Galinpepimut-S and Opdivo Galinpepimut-S and Opdivo are both … Continue reading Early Data Show Promise for Galinpepimut-S and Opdivo in Mesothelioma Patients »

Treatment with Vinorelbine for Relapsed Pleural Mesothelioma

treatment with vinorelbine

A new study suggests that treatment with vinorelbine may boost progression free survival for people with relapsed malignant mesothelioma. Mesothelioma is a virulent cancer caused by exposure to asbestos. Chemotherapy is the primary first-line treatment. But this cancer almost always comes back within a few months.  Now, researchers at the UK’s University of Leicester say treatment with vinorelbine might keep mesothelioma at bay for several months longer. They presented their research at this months’ annual meeting of the American Society of Clinical Oncology.  Second-Line Mesothelioma Treatments Needed Pleural mesothelioma is the most common form of mesothelioma. Tumors grow on the membrane around the lungs. The symptoms often mimic lung cancer but can be even more deadly.  Some of the healthiest … Continue reading Treatment with Vinorelbine for Relapsed Pleural Mesothelioma »

Immunotherapy Treatment ONCOS-102: News Keeps Getting Better

immunotherapy treatment

The news just keeps getting better for the virus-based immunotherapy treatment ONCOS-102.  Norweigian drug maker Targovax recently released the final survival data from a two-year study of ONCOS-102 in people with malignant pleural mesothelioma.  Eighteen months into the study, it looked like some of the patients on the immunotherapy treatment would live longer than two years. Now that the ONCOS-102 study has passed the two year mark, researchers say median survival may be even longer.  Average survival is a year or less on standard mesothelioma therapies. This makes the news about ONCOS-102 especially exciting.  Standard of Care Versus Immunotherapy Treatment Malignant mesothelioma is an aggressive malignancy with a poor prognosis. Even patients in overall good health face a grim outlook. … Continue reading Immunotherapy Treatment ONCOS-102: News Keeps Getting Better »

Effectiveness of Keytruda: Dutch Study Offers Clues for Prediction

effectiveness of Keytruda

A new Dutch study offers some clues that might help doctors predict the effectiveness of Keytruda (pembrolizumab) in individual mesothelioma patients.  Keytruda is the brand name for pembrolizumab. It is an immunotherapy drug called an immune checkpoint inhibitor. It helps unmask mesothelioma cells so that the immune system can find and fight them.  But the effectiveness of Keytruda is not consistent. Some patients respond well while others do not respond at all. The new study looked at how different people metabolize the drug. Understanding this could help doctors determine the best dose for each mesothelioma patient.  Pembrolizumab and its Link to Mesothelioma Survival Malignant pleural mesothelioma is a deadly form of lung cancer. Asbestos exposure is the main cause of … Continue reading Effectiveness of Keytruda: Dutch Study Offers Clues for Prediction »

Get your free copy of
“Surviving Mesothelioma” Today!